(6R,7R)-7-{[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-{[(2-carboxy-2-propanyl)oxy]imino}acetyl]amino}-8-oxo-3-(1-pyridiniumylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate dihydrochloride(CAS: 73547-70-3)

This compound falls under the scope of GHS classification for hazardous chemicals. It is also regulated under REACH in the European Union, which requires notification of manufacturers and importers to ECHA. In the US, FDA and EPA regulations apply for its use and disposal. Detailed safety data sheets (SDS) should be prepared and complied with for handling, storage, and transportation.

Synthetic alternatives include isomers and analogs of the compound, which can be used depending on the specific biological activity required. Common alternative reagents include various amino acids and thiazole derivatives. The choice of alternative depends on the desired pharmacological profile and availability.

Research on this compound is focused on its potential as a therapeutic agent, particularly in the treatment of infectious diseases. Market trends show increasing interest in novel antimicrobial agents. Additionally, there is a growing trend towards personalized medicine and drug discovery, which may lead to further research and development of this compound.

Waste containing this compound should be collected in appropriate containers and stored in a secure, well-ventilated area. Disposal should follow local regulations and be entrusted to a professional waste management company. Environmental precautions include minimizing contact with water sources and soil. Incineration is a common method for disposal, but proper incineration conditions should be maintained to ensure complete combustion and reduction of pollutants.